Loading
A phase 1 trial of KAN-001 run by Kanvas Biosciences, not yet recruiting.
A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer is a phase 1 interventional study registered as NCT07910942 by Kanvas Biosciences, with 40 participants planned, started 2026-11. Conditions recorded: Non-Small Cell Lung Cancer. Interventions recorded: KAN-001 and Pembrolizumab.
Shares Kanvas Biosciences and the tag pipeline.
Shares Kanvas Biosciences and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/